- Home
- CUE vs GNLX Comparison
CUE vs GNLX Comparison
Compare CUE & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- GNLX
- Stock Information
- Founded
- CUE 2014
- GNLX 2001
- Country
- CUE United States
- GNLX United States
- Employees
- CUE N/A
- GNLX N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- CUE Health Care
- GNLX Health Care
- Exchange
- CUE Nasdaq
- GNLX Nasdaq
- Market Cap
- CUE 91.9M
- GNLX 184.4M
- IPO Year
- CUE 2018
- GNLX 2023
- Fundamental
- Price
- CUE $1.49
- GNLX $5.34
- Analyst Decision
- CUE Strong Buy
- GNLX Strong Buy
- Analyst Count
- CUE 5
- GNLX 4
- Target Price
- CUE $5.00
- GNLX $18.25
- AVG Volume (30 Days)
- CUE 254.0K
- GNLX 396.9K
- Earning Date
- CUE 03-10-2025
- GNLX 03-31-2025
- Dividend Yield
- CUE N/A
- GNLX N/A
- EPS Growth
- CUE N/A
- GNLX N/A
- EPS
- CUE N/A
- GNLX N/A
- Revenue
- CUE $9,532,000.00
- GNLX $8,000.00
- Revenue This Year
- CUE $73.11
- GNLX N/A
- Revenue Next Year
- CUE $11.02
- GNLX N/A
- P/E Ratio
- CUE N/A
- GNLX N/A
- Revenue Growth
- CUE 149.53
- GNLX N/A
- 52 Week Low
- CUE $0.45
- GNLX $1.60
- 52 Week High
- CUE $2.37
- GNLX $8.67
- Technical
- Relative Strength Index (RSI)
- CUE 58.61
- GNLX 72.84
- Support Level
- CUE $1.22
- GNLX $4.10
- Resistance Level
- CUE $1.50
- GNLX $5.89
- Average True Range (ATR)
- CUE 0.12
- GNLX 0.54
- MACD
- CUE 0.00
- GNLX 0.14
- Stochastic Oscillator
- CUE 96.67
- GNLX 79.70
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.